Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741097 | 0.88 | PTGS2 (0.39) | PTGS2PTGS1PDE5AGRM2CYP19A1 | |
| SCHEMBL5739073 | 0.87 | PTGS2 (0.42) | PTGS2PTGS1PDE5AGRM2 | |
| SCHEMBL5740330 | 0.85 | CNR1 (0.39) | PTGS2PTGS1MTORPDE5AGRM2 | |
| SCHEMBL5747687 | 0.84 | PTGS2 (0.41) | PTGS2PTGS1MTORPDE5AGRM2 | |
| SCHEMBL5739026 | 0.83 | PTGS2 (0.38) | PTGS2PTGS1MTORPDE5AGRM2 | |
| SCHEMBL5739765 | 0.79 | PTGS2 (0.44) | PTGS2PTGS1PDE5AGRM2CYP19A1 | |
| SCHEMBL4960172 | 0.67 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL4960023 | 0.62 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL2572447 | 0.61 | MTOR (0.45) | MTORGRM2 | |
| SCHEMBL5152024 | 0.61 | PTGS2 (0.53) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270880-A1 | 7-Azaindole derivatives as cox2 inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | US | disclosed |
| EP-1654262-B1 | 7-AZAINDOLE DERIVATIVES AS COX2 INHIBITORS | GLAXO GROUP LTD (GB) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270880-A1 | 7-Azaindole derivatives as cox2 inhibitors | PTGS2, PTGES2, PTGIS | PTGS2 1/4885PTGS1 4/4885MTOR 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.